Is There a Role for Adjuvant Hysterectomy after Suboptimal Concurrent Chemoradiation in Cervical Carcinoma?

被引:15
|
作者
Walji, N. [1 ]
Chue, A. L. [1 ]
Yap, C. [2 ]
Rogers, L. J. [3 ]
El-Modir, A. [1 ]
Chan, K. K. [4 ]
Singh, K. [3 ]
Fernando, I. N. [1 ]
机构
[1] Queen Elizabeth Hosp, Ctr Canc, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Inst Canc Studies, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
[3] City Hosp, Pan Birmingham Gynaecol Canc Ctr, Birmingham, W Midlands, England
[4] Birmingham Womens Hosp, Birmingham, W Midlands, England
关键词
Brachytherapy; cervical carcinoma; chemoradiotherapy; hysterectomy; BRACHYTHERAPY-SOCIETY RECOMMENDATIONS; DOSE-RATE BRACHYTHERAPY; UTERINE CERVIX; RADIATION-THERAPY; STAGE-IB; EXTRAFASCIAL HYSTERECTOMY; CANCER; SURGERY; RADIOTHERAPY; SURVIVAL;
D O I
10.1016/j.clon.2009.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Failure to carry out intracavitary brachytherapy (ICBT) in cervical carcinoma results in suboptimal chemoradiation and increases the Fisk of recurrence. The aim of this study was to investigate the role of adjuvant hysterectomy after unsuccessful ICBT. Materials and methods: A retrospective analysis was carried out of all women referred with cervical carcinoma between January 1999 and July 2007 where ICBT insertion was unsuccessful after the initial chemoradiation. The data collected and analysed included histology, stage of disease, causes for unsuccessful ICBT insertion, the response to the initial chemoradiation, subsequent treatment, morbidity, recurrence rates and survival rates. Kaplan-Meier and Log-rank methods were used to analyse recurrence-free and overall Survival rates. Results: ICBT insertion was unsuccessful in 19 of 208 (9%) patients. The causes of failure were: inability to dilate the cervix; uterine perforation; vesicovaginal fistula; patient refusal; other problems, including the presence of pyometrium, patient not fit for general anaesthetic, and narrow vagina; and consultant choice with no obvious reason. Fourteen of 19 patients (74%) received further pelvic external beam radiotherapy (EBRT) alone; five (26%) patients underwent adjuvant hysterectomy. The median follow-up for all patients was 63 months; 60 months for patients treated with adjuvant hysterectomy (range 31-68 months) and 85 months for patients treated with further EBRT. None of the patients treated with adjuvant hysterectomy developed any significant late toxicity. Seven patients (50%) treated with EBRT have relapsed compared with none in the adjuvant hysterectomy arm (P = 0.068). Six patients (43%) in the EBRT arm have subsequently died of recurrent disease compared with none in the adjuvant hysterectomy arm (P = 0.152). Conclusions: Adjuvant hysterectomy after unsuccessful ICBT does not seem to increase late toxicity and reduces the Fisk of pelvic recurrence and may improve survival. The role of adjuvant hysterectomy after suboptimal chemoradiation merits further investigation in clinical trials. (C) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 50 条
  • [11] Concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for cervical carcinoma
    Ha, SW
    Kim, K
    Lee, H
    Kang, S
    Wu, H
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S302 - S302
  • [12] Concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for cervical carcinoma
    Kim, K
    Lee, H
    Kang, S
    Wu, H
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S167 - S167
  • [13] ADJUVANT CHEMOTHERAPY AFTER RADICAL HYSTERECTOMY FOR CERVICAL-CARCINOMA
    LAI, CH
    LIN, TS
    SOONG, YK
    CHEN, HF
    GYNECOLOGIC ONCOLOGY, 1989, 35 (02) : 193 - 198
  • [14] Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer The STARS Phase 3 Randomized Clinical Trial
    Huang, He
    Feng, Yan-Ling
    Wan, Ting
    Zhang, Yan-Na
    Cao, Xin-Ping
    Huang, Yong-Wen
    Xiong, Ying
    Huang, Xin
    Zheng, Min
    Li, Yan-Fang
    Li, Jun-Dong
    Chen, Guan-Di
    Li, Hu
    Chen, Yi-Le
    Ma, Li-Guo
    Yang, Hong-Ying
    Li, Li
    Yao, Shu-Zhong
    Ye, Wei-Jun
    Tu, Hua
    Huang, Qi-Dan
    Liang, Li-Zhi
    Liu, Fu-Yuan
    Liu, Qing
    Liu, Ji-Hong
    JAMA ONCOLOGY, 2021, 7 (03) : 361 - 369
  • [15] ROLE OF COMPLETION HYSTERECTOMY AFTER CONCOMITANT CHEMORADIATION IN CERVICAL CANCER OUTCOME
    Truffa Kleine, R.
    Sadalla, J. C.
    Genta, M. L. N. D.
    Suarez, G. M.
    de Carvalho, J. P. M.
    Mauro, G. P.
    Anton, C.
    Carvalho, J. P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A95 - A96
  • [16] Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: A comparison with effects of adjuvant radiotherapy
    Iwasaka, T
    Kamura, T
    Yokoyama, M
    Matsuo, N
    Nakano, H
    Sugimori, H
    OBSTETRICS AND GYNECOLOGY, 1998, 91 (06): : 977 - 981
  • [17] Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.
    Kou, Lingna
    Zhang, Tao
    Peng, Siyun
    Wang, Yifei
    Yuan, Mingyang
    Li, Minmin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] Is concurrent chemoradiation a choice for high-risk cervical cancer patients after radical hysterectomy?
    Wang, Peng-Hui
    Cheng, Ming-Huei
    Yuan, Chiou-Chung
    Yen, Ming-Shyen
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (01) : 102 - 103
  • [19] Total Laparoscopic Resection Surgery for a Cervical Carcinoma that Recurred in the Pelvic Sidewall After Radical Hysterectomy and Adjuvant Concurrent Chemoradiotherapy
    Kanao, Hiroyuki
    Aoki, Yoichi
    Kato, Kazuyoshi
    Matoda, Maki
    Okamoto, Sanshiro
    Nomura, Hidetaka
    Omatsu, Kohei
    Utsugi, Kuniko
    Takeshima, Nobuhiro
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2017, 24 (06) : 899 - 900
  • [20] The Efficacy of Adjuvant Hysterectomy after Definitive Radiotherapy or Concurrent Chemoradiotherapy in Patients with Cervical Adenocarcinoma
    Ma, J.
    Hu, K.
    Zhang, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E330 - E330